Background The aim of this study was to determine compliance with published good practice guidelines for gender and clinical trials using etoricoxib. The rationale for choosing etoricoxib was that it is widely used by women and there is evidence of potential interaction with contraceptives and hormone replacement therapy as highlighted in the product characteristics.
Introduction
Previous studies on cyclooxygenase-2 inhibitors (coxib) have described cardiovascular damage related to their use. 1, 2 The effects of rofecoxib, for example, were so serious that it was taken off the market. 3 These studies highlight a series of doubts concerning the risk-benefit relationship of this type of drug. 3 While a greater risk may be acceptable in drugs with essential therapeutic actions in severe conditions, in the case of this type of drugs, which are mostly used to control symptoms of non-fatal diseases, the tolerance to severe side effects should be minimal.
Women are by far the greatest consumers of coxib ( just over 85%) as stated by post-marketing studies. 4, 5 However, the design of clinical trials on efficacy seems to under-represent them according to their prevalence of consumption. 6 In research dealing with risks related to coxib, it has been found that women are also under-represented with regard to the said prevalence of consumption. Specifically, in a postmarketing case and control study that attempted to identify the association between coxib and myocardial infarction and digestive problems, it was seen that more men were used as study subjects than women. 7 More men may have been included in the study than women based on the erroneous perception that there exists a higher prevalence of myocardial infarction amongst men, a theory that has been disproved. 8, 9 Etoricoxib is the latest coxib to be developed and is administered for symptomatic relief of problems related to arthrosis, rheumatoid arthritis and inflammation due to acute gout, although it has also been tested for ankylosing spondylitis, low back pain and other types of acute pain. 10 As with other coxib, the safety of etoricoxib has also been criticized. 10, 11 Not even the most in-depth clinical trial on etoricoxib has been able to clear up doubts surrounding its safety. 12 With regard to safety by sex, the aforementioned trial detected greater risks of thrombosis in women, although differences were not statistically significant. 12 The summary of product characteristics for etoricoxib approved by the European Medicines Agency (EMEA) also describes the interaction of this drug with contraceptives and hormone replacement therapy. The clinical consequences for women, according to the aforementioned document, remain unknown, thus possibly increasing the risk of adverse effects related to this type of hormone therapy. 13 Specifically, in fertile women, the administration of 60 mg of etoricoxib together with an hormonal contraceptive containing ethinyl estradiol increases exposure to the latter, thus possibly exacerbating the adverse effects associated with hormonal contraceptives. 13 In menopausal women, the most likely group to consume this drug, administering 120 mg of etoricoxib also increases estrogenic exposure when administered concomitantly with conjugated estrogen. 13 The potential risk of etoricoxib in pregnant human subjects is also unknown, although a certain level of toxicity has been reported in pregnant animals. 13 Other coxib have reduced preterm births whilst rofecoxib has a local negative effect on human ovulation, possibly causing delayed follicular rupture. 13, 14 Etoricoxib inhibits the synthesis of prostaglandins and may produce uterine inactivity and prematurely close the ductus arteriosus. Other effects of coxib on human reproduction remain uncertain and require greater attention by those who treat young women with chronic inflammatory diseases. 15 In 2007, the Food and Drug Administration (FDA) Arthritis Drugs Advisory Committee rejected the commercialization of this new drug and requested the risk -benefit profile data for the proposed doses of etoricoxib for future approval of its commercialization. 16 Nevertheless, etoricoxib is available in 68 countries in Europe, Latin America, the Asia-Pacific region, the Middle East and North Africa. 17 The EMEA published a document on its website which, despite recognizing that gender may influence response to drugs, states that the publication of specific guidelines is not necessary given that International Conference on Harmonization (ICH) guidelines already exist. 18 Unfortunately, the ICH guidelines suggest that 'if the size of the study permits, important demographic or baseline value-defined subgroups should be examined', which is not always viable as sex is not considered as a relevant variable in clinical trial design. Furthermore, the under-representation of women in clinical trials and the lack of sex stratification reflect the methodological problems of clinical research from a gender perspective. 6,19 -27 It is therefore surprising that the data presented in the summary of product characteristics approved by the EMEA states that the pharmacokinetics of etoricoxib is similar in both sexes. 12 As proposed in the Revitalization Act by the National Institute of Health in the USA in the 1990s, it is important to include women and gender analysis in clinical research. 28 With this in mind, the FDA published in 1993 its recommendations in the Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs. 29 Furthermore, in 2007, the consensus report was presented by the Sex, Gender and Pain Special Interest Group (SIG) of the International Association for the Study of Pain. 30 Our aim was to determine compliance with published good practice guidelines for gender and clinical trials using etoricoxib. The rationale for choosing etoricoxib was that it was it is used widely by women and there is evidence of potential interaction with contraceptives and hormone replacement therapy as highlighted in the product characteristics.
Methods
A review was performed on the etoricoxib human clinical trials indexed in Medline and Cochrane Library published between January 2000 and December 2007. 11,21 -73 A total of 54 papers describing 58 trials of etoricoxib on adults were identified and reviewed. In the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme, it should be highlighted that three trials were involved [Etoricoxib vs. Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) I, EDGE II and MEDAL]. Although the results from both EDGE I and EDGE II had been published previously, the information of the participants from the three studies was published in the MEDAL Programme Report. 12 Therefore, we have considered the whole programme as just one trial.
The characteristics of each clinical trial can be viewed in Table 1 ( phase, number of participants, number of women and men, age of participants and their health/disease condition). The trials were ordered according to phase, year of publication and first author.
A specific protocol was created for the gender analysis, based on the recommendations in the FDA guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drug 29 and the Sex, Gender and Pain SIG Consensus Working Group Report. Table 2 displays the criteria used for the inclusion of clinical trials under each gender analysis variable and the references of the trials included: † Sex differences (stratified data in order to enable gender analysis of the results, analysis by gender of: efficacy, adverse effects, dose-response, blood concentrationresponse and discussion of the results by sex). Continued † Women-specific issues ( pregnancy as an exclusion criterion, use of contraceptive methods, use of hormonal contraceptives, use of hormone replacement therapy, menstrual cycle and menstrual status).
Sensitivity was the main criterion for considering that a clinical trial fulfilled a sex-related recommendation, if there were any mention of the sex variable in the text.
A descriptive study of frequencies and percentages was performed for the aforementioned variables (Table 3) . Subsequently, the level of inter-observer agreement (authors E.C. and M.T.R.) was calculated by means of the Kappa index and a high level of agreement was obtained (Kappa index ¼ 95%). Any lack of agreement (5%) was resolved by a third researcher (A.P.).
After data collection, and via email, we attempted to contact the 44 authors of the 54 papers that had published the 58 clinical trials on etoricoxib in order to discover any information about sex differences and gender information that had not been published in their papers. Thirty-two authors had declared a conflict of interest in the articles themselves, and/or had received funding from Merck Sharp & Dohme, the company that owns etoricoxib.
Results
A total of 51 619 subjects took part in the 58 trials described in the 54 papers and published between 2000 and 2007.
12, 31 -83 There were 12 Phase I trials, 9 Phase II trials and 37 Phase III trials. It was possible to determine the number of women and men participants in 56 trials, a total of 49 835 individuals: 35 182 (70%) were women and 14 653 (30%) were men. Nine trials included just one sex: five of which included only men and four were Phase I trials.
The four trials that included only women were sex specific. With regard to the trials that included both sexes (49 trials), 42 clinical trials (83.7%) involved a lower percentage of women than the prevalence of consumption (current consumption is 85% in women) and only five included a percentage of women close to 80% (two trials did not give information about the percentage of women and men). Phase I trials accounted for 330 participants and, of these, only 31% (103) were women. Table 3 summarizes the number of trials that did not include a sex analysis: 42 clinical trials (85.7%) did not present sex-stratified data, 30 trials (90.6%) did not provide efficacy data by sex, 42 trials (93.3%) did not show the adverse effects information by sex, 16 trials (100%) did not report the dose -response relationship by sex, six trials (100%) did not provide the analysis of the blood concentration-response by sex and 47 trials (95.9%) did not include any discussion of results by sex. There were just two clinical trials that mentioned gender differences with regard to the response to etoricoxib in their discussion. 40, 78 The three trials (9.9%) that included the analysis of efficacy by sex concluded that there were no sex differences. 56, 69, 78 Three of the 45 studies which included adverse effects present this information by gender. 12, 40, 78 Data provided by Cannon et al. noted sex differences in thrombotic events but without significance. Hunt et al. 12 reported sex differences in gastrointestinal events, where being male was considered a risk factor. 40 Although Navarra et al. found there to be no relationship between sex and efficacy and adverse effects, they admitted that only a few women had been included in the sample population, thus making it impossible to obtain the significance of this finding, despite the fact that the aim of the trial was to detect differences between demographic characteristics. NA, not applicable; ND, non-data. [11] Men are more likely to suffer gastrointestinal events [40] There is no difference [78] Analysis Number of women on this treatment [80] Differences in response between women using hormonal contraceptives and those who do not With regard to women-specific issues, Table 3 also shows that 20 clinical trials (43.5%), which included women of a childbearing age, did not mention pregnancy as an exclusion criterion and 37 trials (78.7%) did not refer to the recommendation of contraceptive methods to avoid pregnancy during the trial. The two trials that mentioned the specific use of hormonal contraceptives (one to prohibit them 56 and the other merely to give the number of women receiving such treatment) did not use this information in the analysis of the results. 80 None of the trials mentioned the differences in response between women using oral contraceptives and those who are not.
METHODOLOGICAL GENDER BIAS
Of the 42 trials that included women in the age range for hormone replacement therapy, none stated the number of women on such a regime or whether the differences between women receiving and women not receiving hormonal replacement therapy were examined. The results reveal that none of the 47 trials that included women of a childbearing age evaluated the effects of the phases of the menstrual cycle in response to etoricoxib. None of the trials revealed the influence of menstrual status on the etoricoxib pharmacokinetics or the performed comparisons of pre-menopausal and menopausal women. Furthermore, the influence of concomitant hormone replacement therapies or systemic contraceptives on etoricoxib pharmacokinetics was not shown, neither was the influence of etoricoxib on the pharmacokinetics of oral contraceptives, although women who were taking oral contraceptives were included in the trials.
Finally, 6 of the 44 authors responded to two questions via e-mail: (i) if sex differences were considered in the initial clinical trial design and (ii) if sex differences were actually analysed, why were they not published. The response rate was 13.6% (6.3% from authors who declared conflict of interests and 33.3% from authors with no conflict of interests). Their answers were as follows: (i) 'The sample size was insufficient to detect such differences', 78 (ii) 'No sex analysis had been carried out in his clinical trial on the efficacy and adverse effects of etoricoxib, but that subsequent studies on the need for analgesic during the post-operative phase had detected sex differences', 46 (iii) 'Only important results were published', 70 (iv) 'Had not considered analysis by subgroups due to the fact that the groups were generally too small to obtain any statistical significance' 46, 69 and (v) 'The greater frequency of allergic reactions to antiinflammatories in women is already widely known'.
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Discussion
The main findings of this study Etoricoxib is marketed in Europe with scarce gender-specific knowledge regardless of the fact that this drug is consumed by a significant number of women, and the evidence of potential interaction with contraceptives and hormone replacement therapy as highlighted in the product characteristics. 13 Considering the prevalence of etoricoxib consumption in women, this population group is under-represented in the published etoricoxib clinical trials. Specifically, women are under-represented in Phase I trials despite the fact that some sex differences in pharmacokinetics and pharmacodynamics can only be detected during this first phase.
The findings of this review show that sex-stratified data on efficacy and adverse effects are scarce in the articles published on etoricoxib clinical trials, which hinders gender analysis of the results. Moreover, there is a lack of data on women-specific issues in those articles, such as interaction with hormone treatment. This suggests that etoricoxib may represent the same potential problems for women as other coxib. 12 Etoricoxib is an example of what could happen with other published clinical trials carried out on other drugs with regard to the validity problems and the inferential capacity for women.
What is already known on this topic?
The influence of gender policy on new drug trial reports is still limited, as has been revealed by other papers on a number of conditions. 18 -27 These articles recognize that whilst some trials comply with gender recommendations, both with regard to female participation and gender analysis, others do not.
Although low participation of women persists, the emphasis has now shifted from their representation in clinical trials to the importance of carrying out a gender analysis on subgroups focused on a broader examination of efficacy and safety, and the study of interactions between endogenous and exogenous hormones and the drug in question. 29, 30, 84 It has therefore been proposed that a consensus be reached on the need to analyse subgroups in order to detect sex differences and to include sex as a covariant in more in-depth clinical trials. 29 In the specific case of pain treatment, the differences in response to drugs between men and women are well known. 26 The cohort study of the Health Technology Assessment (HTA) Report detected sex differences with regard to adverse gastrointestinal effects, signalling males as a risk group. 26 However, this result, together with other information concerning adverse effects by sex, had not been registered in the clinical trials reviewed. The Sex, Gender and Pain SIG Consensus Working Group Report suggests that trials on analgesics should increase their statistical power in order to detect sex differences with regard to efficacy and adverse effects. 30 Nevertheless, cardiovascular problems are the main concern with regard to the safety of coxibs 3 and not gastrointestinal complaints. The risk-benefit relationship of the coxibs is still in debate in the scientific literature. 1 -3,85 Even the EMEA and the FDA are positioned in different ways in relation to these drugs. The FDA and the EMEA have taken different precautions: the FDA uses the black box on celecoxib and traditional non-steroideal anti-inflammatories whereas the EMEA on celecoxib and etoricoxib. The FDA rejected the commercialization of etoricoxib whereas EMEA approved it, as we mentioned. 85 According to data published on the safety of coxib, there exists a degree of disparity in the results of the clinical trials with regard to sex. Bresalier et al.
1 found that patients with colorectal adenoma treated with rofecoxib manifested an increase in the number of thrombotic events, although no sex differences were detected. However, Solomon et al.
2 treated the same kind of patients with celecoxib and also found an increase in thrombotic events, but which was greater in men. On the other hand, Egan et al. 86 showed how coxib blocked the protective effects of estrogens on cardiovascular diseases by regulating the production of prostaglandins. Although the experiment was carried out on mice, cardiologists believe that the loss of prostaglandins, which occurs when taking rofecoxib, could increase the specific risks related to coxib. 86, 87 Those who oppose the inclusion of sex stratification and gender analysis in clinical trial results highlight the increased cost it would involve. However, as the 2007 Financial Report highlights, the owner of etoricoxib spent less on R þ D (20.51% of the budget) than on marketing and administration (31.75%). 88 Besides, if the idea is to try to help improve health, it should be taken into account that in the US alone, 8 out of 10 drugs taken off the market in the 1990s involved a higher risk for women than for men. 89 
What this study adds
The FDA guidelines on the distribution of clinical trial patients by sex indicate that the trials should reflect the population of patients that will use the drug once it is on the market. 29 The published etoricoxib clinical trials do not reflect the consumer population of this drug.
The published Phase I etoricoxib clinical trials also follow this pattern in the sense that women are under-represented when compared with men, as was also described in the review of the clinical trials published in three important clinical pharmacology journals in 2005. 27 This is an extremely important point as it underlines the need to include women in Phase I trials and to carry out and publish pilot studies that would detect possible sex differences in pharmacokinetics and pharmacodynamics before the definitive control tests are performed, as it is during these phases that basic information is obtained for the design of the later phases of the etoricoxib trials. For this to occur, the need to apply different therapeutic regimes with regard to dosage by sex must be recognized. 29 After reviewing the publications available on etoricoxib, it may seem that the reason for not mentioning sex differences in the results is that there really are no such differences, as alleged by the authors of the clinical trials on the efficacy of etoricoxib by sex. 56, 69, 78 However, the interviewed authors by our e-mail query indicate alternative arguments related to insufficient sample size to detect such differences. 78 Furthermore, another answer was that no sex analysis had been carried out, 46 but that subsequent studies on the need for analgesics during the post-operative phase had detected sex differences.
In the HTA Report, it was indicated that no sex differences were registered with regard to adverse effects in the clinical trials reviewed. 26 This could be due to the absence of a sex analysis of the results, the possible publication bias of the trial sponsors or to the fact that no significant differences by sex were detected in the trials as the trial design did not contemplate a sufficient sample of both men and women. It is possible that the etoricoxib clinical trials may be further example of such problems that can arise in methodology and scientific policy issues.
Only three clinical trials analysed sex differences related to adverse effects. In one trial, sex differences are detected in gastrointestinal events, showing that men are more likely to suffer this effect than women. 40 In another trial, no differences are detected but the authors argue that this is due to the small sample size 78 and MEDAL performs an analysis on subgroups that reveals a greater frequency of thrombotic events in women than in men. 12 Some authors who responded to our e-mail query admitted that they had not considered an analysis by subgroups due to the fact that the groups were generally too small to obtain any statistical significance. 46, 69 Therefore, as Fitzgerald points out, 'the absence of evidence is not the evidence of absence'. 3 It is interesting that in the summary of product characteristics of etoricoxib, interactions are described between etoricoxib and hormone treatment 12 when evidence has not been provided of this in either Phase I or later phases of the etoricoxib clinical trials. Neither has the possible influence of the menstrual cycle and menstrual status been indicated on the effects of taking etoricoxib, despite the recommendations by the FDA or the Sex, Gender and Pain SIG Consensus Working Group. 29, 30 It is possible to correct a gender bias by complying more strictly with scientific research methodological norms. 90 In the same way as evidence-based medicine, gender-based medicine expects the results of research such as clinical trials to strengthen their validity. It is essential that the sex variable be considered as a determining factor in drug consumption from the very beginning of the clinical trial, i.e. during the design stage, to enable a sex-stratified analysis of the data at a later stage and to detect sex differences in patients' responses to drugs.
Limitations
This research is based on the sex differences and gender analysis of the etoricoxib clinical trials, which does not mean to say that sex and gender are the only relevant characteristics to be investigated. Other variables such as age and ethnic group also require further attention. This article reviews etoricoxib clinical trials published in medical journals and indexed in Medline and Cochrane, thus the conclusions reached are limited to the clinical trials published which, nevertheless, have been evaluated by independent peer reviewers. However, there is a lack of information by sex on any unpublished etoricoxib clinical trials. The surveillance data on the Merck website, which supported 81% of the published clinical trials, have no more information by sex. The few authors who responded to our e-mail questionnaire present a range of different answers with regard to the reasons for not including sex stratification in their write up of the etoricoxib clinical trial results, which would suggest the need to include a gender analysis in clinical trials on drugs such as etoricoxib.
